LeishmaniasisTranslation

 

  • Target disease: Post kala-azar dermal leishmaniasis (PKDL) and cutaneous leishmaniasis (CL)
  • Main partners (since project start): Amatsi Aquitaine, France; GeneDesign Inc, Japan; Nagasaki University, Japan; National Institutes of Health, USA; Ohio State University, USA; University of Osaka, Japan; US Food and Drug Administration, USA.
  • Project Start: June 2014
  • Funding: Department for International Development (DFID), UK; Global Health Innovative Technology (GHIT) Fund, Japan; Special Programme for Research and Training in Tropical Diseases (WHO-TDR).

 

Overall Objective:

  • Demonstrate the suitability of CpG-D35, an immunomodulator to stimulate the innate immune system to fight the parasitic infection responsible for CL, as an adjunct to drug therapy, for progression to Phase 1 clinical studies

 

CpG-D35 is being developed as a combination therapy for the treatment of complicated CL and post-kala-azar dermal leishmaniasis (PKDL) in partnership with GeneDesign. Leishmania parasites are able to persist in host cells by evading or exploiting immune, mechanisms. Modulating the immune response with CpG oligonucleotides may improve the effectiveness of chemotherapies.

 

Final results of the preclinical in vivo efficacy study showed an improved outcome for CpG-D35, either alone or in combination with pentavalent antimony (glucantime). These results supported the completion of the pre-clinical package and initiation of the preparation of clinical supplies for a Phase I study.  

Two studies, one in vitro and one in vivo, were initiated in 2016. The in vivo study aims to demonstrate if CpG-D35 – whether alone or in combination with antimonials chemotherapy – will lead to improved leishmania infection outcomes, compared with antimonials alone. Results are expected by mid-2017. The in vitro study aims to assess the stimulatory capability of CpG-D35 in both peripheral blood mononuclear cells and whole blood samples from patients with both CL, due to different leishmania species, and PKDL patients and to determine which host genes are modulated in these two conditions. Results are expected by the end of 2017.

IND-enabling pre-clinical safety prerequisites and service providers for entry into Phase I proof-of-concept clinical trials were identified.

 

Last update: March 2018